


## PHARMACEUTICAL 2021



## MERRIMACK PHARMACEUTICALS **INC** Rank 80 of 409





## PHARMACEUTICAL 2021



## MERRIMACK PHARMACEUTICALS INC

Rank 80 of 409

The relative strengths and weaknesses of MERRIMACK PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MERRIMACK PHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 259% points. The greatest weakness of MERRIMACK PHARMACEUTICALS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 169% points.

The company's Economic Capital Ratio, given in the ranking table, is 61%, being 415% points above the market average of -355%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 16,544            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 770               |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 232               |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | -2,125            |
| Other Liabilities                           | 0                 |
| Other Net Income                            | -141              |
| Property and Equipment                      | 0                 |
| Research and Development                    | 0                 |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 5,012             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 16,776            |
| Liabilities              | 770               |
| Expenses                 | 2,887             |
| Stockholders Equity      | 16,006            |
| Net Income               | -3,028            |
| Comprehensive Net Income | -3,028            |
| Economic Capital Ratio   | 61%               |